Fidelity Investments
RXRX icon

Fidelity Investments’s Recursion Pharmaceuticals RXRX Stock Holding History

Fidelity Investments’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$170K Sell
46,356
-690,298
-94% -$2.3M ﹤0.01% 3740
2026
Q1 		$2.26M Sell
736,654
-2,505,238
-77% -$9.68M ﹤0.01% 2596
2025
Q4 		$13.3M Buy
3,241,892
+13,035
+0.4% +$64.6K ﹤0.01% 1922
2025
Q3 		$15.8M Sell
3,228,857
-2,356,001
-42% -$12.4M ﹤0.01% 1826
2025
Q2 		$28.3M Sell
5,584,858
-1,261,984
-18% -$6.2M ﹤0.01% 1584
2025
Q1 		$36.2M Sell
6,846,842
-225,339
-3% -$1.64M ﹤0.01% 1480
2024
Q4 		$47.8M Sell
7,072,181
-1,291,349
-15% -$8.68M ﹤0.01% 1404
2024
Q3 		$55.1M Buy
8,363,530
+170,810
+2% +$1.22M ﹤0.01% 1335
2024
Q2 		$61.4M Sell
8,192,720
-1,068,151
-12% -$9.32M ﹤0.01% 1235
2024
Q1 		$92.3M Sell
9,260,871
-1,636,416
-15% -$18.2M 0.01% 1090
2023
Q4 		$107M Buy
10,897,287
+207,755
+2% +$1.48M 0.01% 981
2023
Q3 		$81.8M Buy
10,689,532
+6,129,935
+134% +$61.2M 0.01% 1057
2023
Q2 		$34.1M Sell
4,559,597
-195,864
-4% -$1.37M ﹤0.01% 1420
2023
Q1 		$31.7M Buy
4,755,461
+289,746
+6% +$2.3M ﹤0.01% 1421
2022
Q4 		$34.4M Buy
4,465,715
+214,551
+5% +$2.1M ﹤0.01% 1405
2022
Q3 		$45.2M Buy
4,251,164
+1,415,312
+50% +$14.3M ﹤0.01% 1279
2022
Q2 		$23.1M Buy
2,835,852
+690,213
+32% +$4.62M ﹤0.01% 1589
2022
Q1 		$15.4M Buy
2,145,639
+615,413
+40% +$6.54M ﹤0.01% 1915
2021
Q4 		$26.2M Sell
1,530,226
-429,737
-22% -$8.09M ﹤0.01% 1694
2021
Q3 		$45.1M Sell
1,959,963
-251,638
-11% -$7.13M ﹤0.01% 1452
2021
Q2 		$80.7M Buy
+2,211,601
New +$65.5M 0.01% 1213

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments's RXRX Position: Q2 2026 in Review

Fidelity Investments reduced its Recursion Pharmaceuticals (RXRX) stake by 94% in Q2 2026, selling an estimated $2.3M and leaving 46,356 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #3740.

Fidelity Investments first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $107M in Q4 2023. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Fidelity Investments held 46,356 shares of Recursion Pharmaceuticals worth $170K as of Q2 2026.
  • Fidelity Investments sold 690,298 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.3M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3740 holding.
  • Fidelity Investments first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Fidelity Investments's Recursion Pharmaceuticals position peaked at $107M in Q4 2023.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.